Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

被引：0

作者：

Lowell L. Hart

Renata Ferrarotto

Zoran G. Andric

J. Thaddeus Beck

Janakiraman Subramanian

Davorin Z. Radosavljevic

Bojan Zaric

Wahid T. Hanna

Raid Aljumaily

Taofeek K. Owonikoko

Didier Verhoeven

Jie Xiao

Shannon R. Morris

Joyce M. Antal

Maen A. Hussein

机构：

[1] Florida Cancer Specialists,Medical Oncology

[2] Wake Forest University School of Medicine,Department of Medicine

[3] University of Texas MD Anderson Cancer Center,Department of Thoracic and Head and Neck Medical Oncology

[4] Clinical Hospital Center Bezanijska Kosa,Medical Oncology Department

[5] Department of Medical Oncology and Hematology,Department of Medicine

[6] Highlands Oncology Group,Faculty of Medicine, Institute for Pulmonary Diseases of Vojvodina

[7] Saint Luke’s Hospital,Hematology/Oncology

[8] Institute for Oncology and Radiology of Serbia,Stephenson Cancer Center

[9] University of Novi Sad,Department of Hematology and Medical Oncology

[10] University of Tennessee Graduate School of Medicine,Department of Medical Oncology, AZ Klina Brasschaat

[11] University of Oklahoma,Department of Oncology

[12] Sarah Cannon Research Institute,undefined

[13] Emory University,undefined

[14] University of Antwerp,undefined

[15] G1 Therapeutics,undefined

[16] Inc.,undefined

[17] Florida Cancer Specialists,undefined

来源：

Advances in Therapy | 2021年 / 38卷

关键词：

Anemia; Chemotherapy; Myelopreservation; Myelosuppression; Neutropenia; Patient-reported outcomes; Small cell lung cancer; Topotecan; Trilaciclib;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：350 / 365

页数：15

共 50 条

[41] AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study
Rini, B. I.
Szczylik, C.
Tannir, N. M.
Koralewski, P.
Tomczak, P.
Deptala, A.
Kracht, K.
Sun, Y.
Puhlmann, M.
Escudier, B.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
[42] LACK OF EFFECT OF SECUKINUMAB TREATMENT ON THE LIPID PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II STUDY
Durez, P.
Genovese, M.
Kellner, H.
Codding, C.
Ligozio, G.
Richards, H.
Escrig, C.
Mpofu, S.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 194 - 195
[43] Angiotensin II as an alternative nonadrenergic Vasopressor Results of a randomized, double-blind, placebo-controlled Efficacy Study
Duenser, M.
Meier, J.
MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN, 2017, 112 (06) : 540 - 542
[44] A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma
Cui, Chuanliang
Mao, Lili
Chi, Zhihong
Si, Lu
Sheng, Xinan
Kong, Yan
Li, Siming
Lian, Bin
Gu, Kangsheng
Tao, Min
Song, Xin
Lin, Tongyu
Ren, Xiubao
Qin, Shukui
Guo, Jun
MOLECULAR THERAPY, 2013, 21 (07) : 1456 - 1463
[45] Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
Karlan, Beth Y.
Oza, Amit M.
Richardson, Gary E.
Provencher, Diane M.
Hansen, Vincent L.
Buck, Martin
Chambers, Setsuko K.
Ghatage, Prafull
Pippitt, Charles H., Jr.
Brown, John V., III
Covens, Allan
Nagarkar, Raj V.
Davy, Margaret
Leath, Charles A., III
Hoa Nguyen
Stepan, Daniel E.
Weinreich, David M.
Tassoudji, Marjan
Sun, Yu-Nien
Vergote, Ignace B.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04) : 362 - 371
[46] Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer
Spigel, David R.
Burris, Howard A., III
Greco, F. Anthony
Shipley, Dianna L.
Friedman, Elke K.
Waterhouse, David M.
Whorf, Robert C.
Mitchell, R. Brian
Daniel, Davey B.
Zangmeister, Jeffrey
Bass, J. David
Hainsworth, John D.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2582 - 2589
[47] Lanreotide in Patients with Lung Neuroendocrine Tumors: The Randomized Double-Blind Placebo-Controlled International Phase 3 SPINET Study
Reidy-Lagunes, Diane
Kulke, Michael
Wolin, Edward
Singh, Simron
Ferone, Diego
Hoersch, Dieter
Mirakhur, Beloo
Hoffmanns, Philipp
Houchard, Aude
Caplin, Martyn
Baudin, Eric
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1516 - S1517
[48] A randomized double-blind placebo-controlled phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer
Spigel, David R.
Anthony, Greco F.
Burris, I. I. I. Howard A.
Shipley, Dianna L.
Friedman, Elke K.
Waterhouse, David M.
Whorf, Robert C.
Mitchell, Brian R.
Daniel, Davey B.
Zangmeister, Jeffery
Sarnoff, Vicki
Hainsworth, John D.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S355 - S355
[49] Efficacy and safety of oxycodone DETERx: results of a randomized, double-blind, placebo-controlled phase III study
Kopecky, E.
O'Connor, M.
Varanasi, R.
Saim, S.
Fleming, A.
JOURNAL OF PAIN, 2015, 16 (04): : S87 - S87
[50] A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF METHYLPHENIDATE FOR REDUCTION OF FATIGUE IN PROSTATE CANCER PATIENTS RECEIVING LHRH-AGONIST THERAPY
Richard, Patrick O.
Fleshner, Neil E.
Bhatt, Jaimin R.
Hersey, Karen M.
Chahin, Rehab
Alibhai, Shabbir M. H.
JOURNAL OF UROLOGY, 2014, 191 (04): : E768 - E768

← 1 2 3 4 5 →